An updated personalized mRNA cancer vaccine has shown encouraging results in melanoma, reducing the risk of recurrence or death by 44% versus standard immunotherapy alone, according to interim Phase 3 data released by Reuters.

The findings add to growing interest in messenger RNA technology beyond infectious disease, with researchers testing whether customized vaccines can help train the immune system to recognize and attack cancer cells more effectively. The study is being closely watched because melanoma remains one of the most aggressive skin cancers.

While the results are promising, the data are still interim and do not mean the treatment is ready for routine use. Larger readouts will be needed to determine how durable the benefit is, whether it improves overall survival, and how it performs across broader patient groups.

If confirmed in final analysis, the vaccine could mark an important step for personalized oncology, where treatment is tailored to each patient’s tumor profile. For now, the trial offers another sign that mRNA-based cancer therapies may be moving closer to practical clinical use.